The SARS-coronavirus Papain-like Protease: Structure, Function and Inhibition by Designed Antiviral Compounds

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2015 Jan 3

PMID 25554382

Citations 443

Authors

Yahira M Baez-Santos

Sarah E St John

Andrew D Mesecar

Affiliations

Soon will be listed here.

Abstract

Over 10 years have passed since the deadly human coronavirus that causes severe acute respiratory syndrome (SARS-CoV) emerged from the Guangdong Province of China. Despite the fact that the SARS-CoV pandemic infected over 8500 individuals, claimed over 800 lives and cost billions of dollars in economic loss worldwide, there still are no clinically approved antiviral drugs, vaccines or monoclonal antibody therapies to treat SARS-CoV infections. The recent emergence of the deadly human coronavirus that causes Middle East respiratory syndrome (MERS-CoV) is a sobering reminder that new and deadly coronaviruses can emerge at any time with the potential to become pandemics. Therefore, the continued development of therapeutic and prophylactic countermeasures to potentially deadly coronaviruses is warranted. The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. Although the primary function of PLpro and 3CLpro are to process the viral polyprotein in a coordinated manner, PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Therefore, targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. This review provides an up-to-date discussion on the SARS-CoV papain-like protease including a brief overview of the SARS-CoV genome and replication followed by a more in-depth discussion on the structure and catalytic mechanism of SARS-CoV PLpro, the multiple cellular functions of SARS-CoV PLpro, the inhibition of SARS-CoV PLpro by small molecule inhibitors, and the prospect of inhibiting papain-like protease from other coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."

Citing Articles

Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.

Jadhav P, Liang X, Ansari A, Tan B, Tan H, Li K Nat Commun. 2025; 16(1):1604.

PMID: 39948104 PMC: 11825904. DOI: 10.1038/s41467-025-56902-x.

Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.

Varghese A, Liu J, Liu B, Guo W, Dong F, Patterson T Molecules. 2025; 30(3).

PMID: 39942596 PMC: 11820935. DOI: 10.3390/molecules30030491.

Thiol-Reactive or Redox-Active: Revising a Repurposing Screen Led to a New Invalidation Pipeline and Identified a True Noncovalent Inhibitor Against Papain-like Protease from SARS-CoV-2.

Kuzikov M, Morasso S, Reinshagen J, Wolf M, Monaco V, Cozzolino F ACS Pharmacol Transl Sci. 2025; 8(1):66-77.

PMID: 39816795 PMC: 11729419. DOI: 10.1021/acsptsci.4c00325.

Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations.

Gu X, Zhang X, Zhang X, Wang X, Sun W, Zhang Y Nat Prod Bioprospect. 2025; 15(1):3.

PMID: 39753911 PMC: 11699025. DOI: 10.1007/s13659-024-00486-4.

Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents.

Kumar V, Zhu J, Chenna B, Hoffpauir Z, Rademacher A, Rogers A J Am Chem Soc. 2025; 147(2):1631-1648.

PMID: 39746101 PMC: 11744766. DOI: 10.1021/jacs.4c11620.

References

Chen X, Chou C, Chang G . Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir Chem Chemother. 2009; 19(4):151-6. DOI: 10.1177/095632020901900402. View

Hagemeijer M, Verheije M, Ulasli M, Shaltiel I, de Vries L, Reggiori F . Dynamics of coronavirus replication-transcription complexes. J Virol. 2009; 84(4):2134-49. PMC: 2812403. DOI: 10.1128/JVI.01716-09. View

Love K, Catic A, Schlieker C, Ploegh H . Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol. 2007; 3(11):697-705. DOI: 10.1038/nchembio.2007.43. View

Lindner H, Lytvyn V, Qi H, Lachance P, Ziomek E, Menard R . Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys. 2007; 466(1):8-14. PMC: 7094341. DOI: 10.1016/j.abb.2007.07.006. View

Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W . Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2007; 82(5):2515-27. PMC: 2258912. DOI: 10.1128/JVI.02114-07. View

Jain R, Pettersson H, Zhang J, Aull K, Fortin P, Huitema C . Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem. 2004; 47(25):6113-6. DOI: 10.1021/jm0494873. View

van Hemert M, van den Worm S, Knoops K, Mommaas A, Gorbalenya A, Snijder E . SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog. 2008; 4(5):e1000054. PMC: 2322833. DOI: 10.1371/journal.ppat.1000054. View

Oostra M, Hagemeijer M, van Gent M, Bekker C, te Lintelo E, Rottier P . Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning. J Virol. 2008; 82(24):12392-405. PMC: 2593338. DOI: 10.1128/JVI.01219-08. View

Egloff M, Malet H, Putics A, Heinonen M, Dutartre H, Frangeul A . Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains. J Virol. 2006; 80(17):8493-502. PMC: 1563857. DOI: 10.1128/JVI.00713-06. View

10.

Hu M, Li P, Li M, Li W, Yao T, Wu J . Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2003; 111(7):1041-54. DOI: 10.1016/s0092-8674(02)01199-6. View

11.

Devaraj S, Wang N, Chen Z, Chen Z, Tseng M, Barretto N . Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007; 282(44):32208-21. PMC: 2756044. DOI: 10.1074/jbc.M704870200. View

12.

Tong T . Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect Disord Drug Targets. 2009; 9(2):223-45. DOI: 10.2174/187152609787847659. View

13.

Imbert I, Snijder E, Dimitrova M, Guillemot J, Lecine P, Canard B . The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res. 2008; 133(2):136-48. PMC: 7114086. DOI: 10.1016/j.virusres.2007.11.017. View

14.

Johnson M, Chatterjee A, Neuman B, Wuthrich K . SARS coronavirus unique domain: three-domain molecular architecture in solution and RNA binding. J Mol Biol. 2010; 400(4):724-42. PMC: 2958096. DOI: 10.1016/j.jmb.2010.05.027. View

15.

Ratia K, Kilianski A, Baez-Santos Y, Baker S, Mesecar A . Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 2014; 10(5):e1004113. PMC: 4031219. DOI: 10.1371/journal.ppat.1004113. View

16.

Ghosh A, Takayama J, Venkateswara Rao K, Ratia K, Chaudhuri R, Mulhearn D . Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J Med Chem. 2010; 53(13):4968-79. PMC: 2918394. DOI: 10.1021/jm1004489. View

17.

Chou C, Lai H, Chen H, Cheng S, Cheng K, Chou Y . Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 2):572-81. PMC: 7161584. DOI: 10.1107/S1399004713031040. View

18.

Snijder E, Bredenbeek P, Dobbe J, Thiel V, Ziebuhr J, Poon L . Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 2003; 331(5):991-1004. PMC: 7159028. DOI: 10.1016/s0022-2836(03)00865-9. View

19.

Wilkinson K, Gan-Erdene T, Kolli N . Derivitization of the C-terminus of ubiquitin and ubiquitin-like proteins using intein chemistry: methods and uses. Methods Enzymol. 2005; 399:37-51. DOI: 10.1016/S0076-6879(05)99003-4. View

20.

Calistri A, Munegato D, Carli I, Parolin C, Palu G . The ubiquitin-conjugating system: multiple roles in viral replication and infection. Cells. 2014; 3(2):386-417. PMC: 4092849. DOI: 10.3390/cells3020386. View